IP Verse

Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor - EP2340828

The patent EP2340828 was granted to Novartis on Jul 15, 2020. The application was originally filed on Nov 8, 2006 under application number EP10176094A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2340828

NOVARTIS
Application Number
EP10176094A
Filing Date
Nov 8, 2006
Status
Granted And Under Opposition
Jun 12, 2020
Grant Date
Jul 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERApr 15, 2021HAMM & WITTKOPPADMISSIBLE
BETAPHARM ARZNEIMITTELApr 15, 2021HAMM & WITTKOPPADMISSIBLE
KRKAApr 15, 2021HOFFMANN EITLEADMISSIBLE
POLPHARMAApr 15, 2021HAMM & WITTKOPPADMISSIBLE
D YOUNGApr 14, 2021D YOUNGADMISSIBLE
STADA ARZNEIMITTELApr 14, 2021KERNEBECKADMISSIBLE
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIApr 7, 2021SONNENHAUSERADMISSIBLE
GENERICS UKJan 19, 2021ELKINGTON AND FIFEADMISSIBLE

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0342850
DESCRIPTIONEP0343911
DESCRIPTIONEP0361365
DESCRIPTIONEP0443983
DESCRIPTIONEP0590442
DESCRIPTIONEP0636621
DESCRIPTIONGB2218983
DESCRIPTIONGB695782
DESCRIPTIONJPH06234754
DESCRIPTIONJPH07157459
DESCRIPTIONUS4610816
DESCRIPTIONUS4722810
DESCRIPTIONUS4929641
DESCRIPTIONUS5217996
DESCRIPTIONUS5223516
DESCRIPTIONUS5250522
DESCRIPTIONUS5273990
DESCRIPTIONUS5294632
DESCRIPTIONUS5399578
DESCRIPTIONWO9009374
DESCRIPTIONWO9214706
DESCRIPTIONWO9309101
DESCRIPTIONWO9310773
DESCRIPTIONWO9415908
DESCRIPTIONZA84670
OPPOSITIONCN105037289
OPPOSITIONEP0034172
OPPOSITIONUS2005070551
OPPOSITIONUS2499058
OPPOSITIONUS2534813
OPPOSITIONUS5217996
OPPOSITIONWO0206253
OPPOSITIONWO03059345
OPPOSITIONWO03089417
OPPOSITIONWO2004078163
OPPOSITIONWO2004083192
SEARCHEP0443983
SEARCHUS5217996
SEARCHWO03059345
SEARCHWO2006086456

Non-Patent Literature (NPL) Citations (56) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHEM PHARM BULL, (2005), vol. 53, page 654-
DESCRIPTION- HYPERTENSION, (1997), vol. 29, pages 428 - 34-
DESCRIPTION- HYPERTENSION, (2004), vol. 44, page 398-
DESCRIPTION- J CLIN PHARMACAL, (1987), vol. 27, page 927-
DESCRIPTION- J HYPERTENS, (2001), vol. 19, page 1923-
DESCRIPTION- LANCET, (2005), vol. 365, page 217-
DESCRIPTION- PATEL MONA, EXPERT OPIN INVESTIG DRUGS, (2003), vol. 12, no. 4, pages 623 - 633-
DESCRIPTION- PEPTIDES, (1988), vol. 9, page 173-
DESCRIPTION- PHARMACOL REV, (1993), vol. 45, page 87-
DESCRIPTION- TRAPANI ET AL., "CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme", J CARDIOVASC PHARMACOL, (2004), vol. 44, no. 1, pages 211 - 5-
OPPOSITION- Aakeröy C. B., "Crystal Engineering: Strategies and Architectures", Christer B., Acta Cryst., (19970000), pages 569 - 586, XP055781013-
OPPOSITION- Aakeröy C. B., "Crystal Engineering: Strategies and Architectures", Christer B., Acta Cryst., (19970101), pages 569 - 586, Christer B., Acta Cryst., (20210302), XP055781013-
OPPOSITION- Aakeroy C. B., "Crystal Engineering: Strategies and Architectures", Christer B., Acta Cryst., (19970101), pages 569 - 586, XP055781013-
OPPOSITION- Anonymous, "Interim Development Report", (20170223), pages 1 - 19-
OPPOSITION- Anonymous, "Nahegelegte Kombination zweier Wirkstoffe einer Arzneimittelzubereitung - Leflunomid", GRUR 2012, 1130 - beck-online, (20120101), pages 1 - 7, GRUR 2012, 1130 - beck-online , URL: https://beck-online.beck.de/Dokument?vpath=bibdata/zeits/GRUR/2012/cont/GRUR.2012.1130.1.htm, (20220929), XP055966479-
OPPOSITION- Anonymous, "Sacubitril and valsartan film-coated tablets 24/26 mg, 49/51 mg , 97/103 mg", Interim Development Report, (20170223), pages 1 - 19, XP055965371-
OPPOSITION- Anonymous, "Sacubitril", Wikipedia, (20210414), pages 1 - 3, URL: https://de.wikipedia.org/wiki/Sacubitril, XP055965361-
OPPOSITION- Anonymous, "Van der Waals forces", Encyclopedia Britannica, (20210413), pages 1 - 2, URL: https://www.britannica.com/science/van-der-Waals-forces, XP055965353-
OPPOSITION- Anonymous, "Van der Waals force", Wikipedia, (20210413), pages 1 - 5, URL: https://en.wikipedia.org/wiki/VanderWaalsforce, XP055965351-
OPPOSITION- Emea, "ICH Topic Q 6 A - Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", CPMP/ICH/367/96, (20000501), pages 1 - 32, XP055966494-
OPPOSITION- European Medicines Agency, "ICH Topic Q 8 Pharmaceutical Development Step 5 NOTE FOR GUIDANCE ON PHARMACEUTICAL DEVELOPMENT (EMEA/CHMP/167068/2004)", EMEA/CHMP/167068/2004 - ICH, (20060501), pages 1 - 9, XP055966547-
OPPOSITION- French W N, Morrison J C, "Identification of Complexes of Phenobarbital with Quinine, Quinidine, or Hydroquinidine in Pharmaceutical Dosage Forms", Journal of Pharmaceutical Sciences, (19650801), vol. 54, no. 8, pages 1133 - 1136, XP055966508-
OPPOSITION- Guillory J Keith, Hwang Soon C, Lach John L, "Interactions Between Pharmaceutical Compounds by Thermal Methods", Journal of Pharmaceutical Sciences, (19690301), vol. 58, no. 3, pages 301 - 308, XP055966511-
OPPOSITION- Hiroshi Fujioka, Takashi Tan, "BIOPHARMACEUTICAL STUDIES ON HYDANTOIN DERIVATIVES. III.PHYSICO-CHEMICAL PROPERTIES, DISSOLUTION BEHAVIOR, AND BIOAVAILABILITY OF THE MOLECULAR COMPOUND OF 1-BENZENESULFONYL-5, 5-DIPHENYLHYDANTOIN AND ANTIPYRINE", Journal of Pharmacobio-Dynamics, (19820101), vol. 5, no. 7, pages 475 - 484, XP055966519-
OPPOSITION- Keiji Sekiguchi, Keiji Ito, "Studies on the Molecular Compounds of Organic Medicinals. I. Dissolution Behavior of the Molecular Compounds of Sulfanilamide and Sulfathiazole", Chemical and Pharmaceutical Bulletin, (19650101), vol. 13, no. 4, pages 405 - 413, XP055966502-
OPPOSITION- "Methods for the characterization Polymorphs", Polymorphism in Pharmaceutical Solids, (19990000), vol. 95, pages 227 - 278, XP008098996-
OPPOSITION- MORISSETTE et al., "High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids", Drug Delivery Reviews, (20040000), vol. 56, no. 3, pages 275 - 300, XP002475812-
OPPOSITION- MORISSETTE SHERRY L ET AL, "High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids.", (20040223), vol. 56, no. 3, pages 275 - 300, XP002475812-
OPPOSITION- Nicola Sardone, G. Bettinetti And M. Sorrenti, "Trimethoprim-Sulfadimidine 1:2 Molecular Complex Monohydrate ", ACTA CRYSTALLOGRAPHICA, (19970101), vol. C53, pages 1295 - 1299, XP055966531-
OPPOSITION- "POLYMORPHISM IN PHARMACEUTICAL SOLIDS /Passage/", Harry G Brittain, POLYMORPHISM IN PHARMACEUTICAL SOLIDS, Marcel Dekker , (19990101), pages iii-ix, 228 - 278, XP055966054-
OPPOSITION- Stahl P H; Wermuth C G, "chapter 12: Monographs on acids and bases", HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, Zürich : Verl. Helvetica Chimica Acta ; Weinheim [u.a.] : Wiley-VCH, DE, (20020000), pages 265 - 327, XP008145189-
OPPOSITION- Stahl P H, Wermuth C G, "chapter 12: Monographs on acids and bases", Stahl P H, Wermuth C G, P. Heinrich Stahl; Camille G. Wermuth (eds.), Handbook of pharmaceutical salts : properties, selection, and use, Weinheim , WILEY-VCH , (20020101), pages 265 - 327, ISBN 978-3-906390-26-0, XP008145189-
OPPOSITION- BERGE S M; BIGHLEY L D; MONKHOUSE D C, "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, (19770000), vol. 66, no. 1, pages 1 - 19, XP000562636
OPPOSITION- BERGE S. M., BIGHLEY L. D., MONKHOUSE D. C., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (19770101), vol. 66, no. 01, doi:10.1002/jps.2600660104, ISSN 0022-3549, pages 1 - 19, XP000562636
OPPOSITION- Bernstein J, Polymorphism in Molecular Crystals, Oxford, Clarendon Press, (20020000), pages 27,46 - 49,112,150,151, XP055312829
OPPOSITION- JOEL BERNSTEIN, "Polymorphism", Polymorphism in Molecular Crystals, Oxford (UK), Clarendon Press, (20020000), pages 27,46 - 49,112,150,151, XP055312829
OPPOSITION- "Polymorphism", J. Bernstein, Polymorphism in Molecular Crystals, Clarendon Press , (20020101), pages 27,46 - 49,112,150,151, doi:10.1007/978-94-010-0546-3_13, XP055312829
OPPOSITION- Mino R. Caira, "Molecular complexes of sulfonamides. 2. 1:1 complexes between drug molecules: sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid", J. Crystallogr. Spectrosc. Res., (19920101), vol. 22, no. 2, doi:10.1007/BF01186256, pages 193 - 200, XP055032899
OPPOSITION- KSANDER et al., "DICARBOXYLIC ACID DIPEPTIDE NEUTRAL ENDOPEPTIDASE INHIBITORS", J. Med. Chem., (19950000), vol. 38, no. 10, pages 1689 - 1700, XP002340280
OPPOSITION- KSANDER G.M.,ET AL., "DICARBOXYLIC ACID DIPEPTIDE NEUTRAL ENDOPEPTIDASE INHIBITORS", Journal of Medicinal Chemistry, American Chemical Society, US, US , (19950101), vol. 38, no. 10, doi:10.1021/jm00010a014, ISSN 0022-2623, pages 1689 - 1700, XP002340280
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, Springer US, New York, New York, (19950701), vol. 12, no. 07, doi:10.1023/A:1016241927429, ISSN 0724-8741, pages 945 - 954, XP000996386
OPPOSITION- DATTA; S; GRANT; D J W, "Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering", Nature Reviews, (20040000), vol. 3, pages 42 - 57, XP009079167
OPPOSITION- DATTA, S., GRANT, D.J.W., "Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering", Nature Reviews. Drug Discovery, Nature Publishing Group, GB, GB , (20040101), vol. 3, no. 1, doi:10.1038/nrd1280, ISSN 1474-1784, pages 42 - 57, XP009079167
OPPOSITION- ALMARSSON et al., "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals reprepsent a new path to improved medicines", Chem. commun., (20040000), pages 1889 - 1896, XP002415977
OPPOSITION- ALMARSSON ET AL., "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals reprepsent a new path to improved medicines.", Chemical Communications, Royal Society of Chemistry, UK, UK , (20040101), doi:10.1039/b402150a, ISSN 1359-7345, pages 1889 - 1896, XP002415977
OPPOSITION- VISHWESHWAR et al., "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients", Chemical Communications, (20050000), no. 36, pages 4601 - 4603, XP002565290
OPPOSITION- VISHWESHWAR P ET AL, "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients", Chemical Communications, Royal Society of Chemistry, UK, UK , (20050928), no. 36, doi:10.1039/b501304f, ISSN 1359-7345, pages 4601 - 4603, XP002565290
OPPOSITION- John J.V. Mcmurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure", New England Journal of Medicine, New England Journal of Medicine, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 00284793, pages 993 - 1004, XP055175908
OPPOSITION- John J V Mcmurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile, "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", NEJM, (20140000), vol. 371, no. 11, pages 1 - 12, XP055175908
OPPOSITION- Sangster James, "Phase Diagrams and Thermodynamic Properties of Binary Systems of Drugs", JOURNAL OF PHYSICAL AND CHEMICAL REFERENCE DATA, AMERICAN CHEMICAL SOCIETY, NEW YORK, NY,, US, US , (19990701), vol. 28, no. 4, doi:10.1063/1.556040, ISSN 0047-2689, pages 889 - 930, XP055966538
OPPOSITION- Nakao S., Fujii S., Sakaki T., Tomita K. I., "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital", ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY., MUNKSGAARD, COPENHAGEN., DK, DK , (19770515), vol. 33, no. 5, doi:10.1107/S0567740877006116, ISSN 0567-7408, pages 1373 - 1378, XP055966525
OPPOSITION- E. VRANI, "Amorphous pharmaceutical solids", BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, (20040000), vol. 4, no. 3, pages 35 - 39, XP055796763
OTHER- Anonymous, "Supramolecular assembly", (20190109), URL: https://en.wikipedia.org/w/index.php?title=Supramolecular_assembly&oldid=877614399, XP055643441-
OTHER- "Supramolecular assembly", Wikipedia, (20190109), URL: https://en.wikipedia.org/w/index.php?title=Supramolecular_assembly&oldid=877614399, XP055643441-
SEARCH- KSANDER G M ET AL, "DICARBOXYLIC ACID DIPEPTIDE NEUTRAL ENDOPEPTIDASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1995), vol. 38, no. 10, ISSN 0022-2623, pages 1689 - 1700, XP002340280 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents